Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Cholicamideβ (compound 6), a self-assembling small molecule cancer vaccine adjuvant, forms low cytotoxicity virus-like particles and upon binding to peptide antigens, enhances dendritic cell-mediated antigen presentation and induces antigen-specific T-cell responses, with the ability to induce apoptosis and necrosis [1]. |
In vitro | Cholicamideβ (compound 6) at concentrations of 4-16 μM induces apoptosis and necrosis in RAW264.7 cells over a period of 22 hours [1]. |
In vivo | Cholicamideβ (compound 6) administered at 100 μg/mouse with evaluation at 16 hours and 21 days post-injection, displayed low toxicity and elevated HA-specific IgG antibody titers [1] in C57BL/6 mice previously immunized with a split influenza vaccine. |
Molecular Weight | 879.34 |
Formula | C55H94N2O6 |
Cas No. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.